Table 2 Baseline characteristics of MSI-H mCRC patient cohort
From: Bayesian additional evidence for decision making under small sample uncertainty
| Characteristic |
Chemotherapy and bevacizumab n = 118 |
Chemotherapy and cetuximab n = 7 | |
|---|---|---|---|
| Median age at 1 L start, years (IQR) | 62 (50, 73) | 65 (60, 76) | |
| Sex, n (%) | Female | 66 (56) | 6 (86) |
| Male | 52 (44) | 1 (14) | |
| Race, n (%) | White | 85 (72) | 5 (71) |
| Other | 14 (12) | 1 (14) | |
| Black/Afr. Am. | 9 (7.6) | 0 | |
| Unknown | 7 (5.9) | 1 (14) | |
| Asian | 3 (2.5) | 0 | |
| BRAF mutation | 26 (22) | 3 (43) | |
| NRAS or KRAS mutation | 15 (13) | 0 | |
| Chemotherapy | FOLFOX | 89 (75) | 3 (43) |
| FOLFIRI | 29 (25) | 4 (57) | |